Antoni Payeras
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Antoni Payeras has a total of 498 co-authors. Here are the top co-authors by number of shared publications:
- Mercedes García-Gasalla
Hospital Son Llàtzer, Palma de Mallorca, Spain
16 shared publications Carmen Cifuentes
Department of Internal Medicine, Hospital Son Llàtzer, Palma de Mallorca
8 shared publicationsMargarita Garau
Servicio de Microbiología, Hospital Son Llàtzer, Palma de Mallorca, España
7 shared publications- Maria Peñaranda
Servicio de Medicina Interna, Hospital Universitario Son Espases, Palma de Mallorca, España
6 shared publications Antoni Bassa
5 shared publications- Diego Viasus
Universidad del Norte and Hospital Universidad del Norte
5 shared publications
Latest Publications
- Open Access
- 9 April 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Impact of bacterial sexually transmitted infections on human papillomavirus and anal dysplasia in people living with HIV
Anal carcinoma is a relevant malignancy with increased incidence among people living with HIV (PLHIV), particularly in men who have sex with men (MSM) and transgender women (TW). Its main precursor lesion, high-grade anal intraepithelial neoplasia (HGAIN), is primarily associated with persistent infection with human papillomavirus (HPV). However, bacterial sexually transmitted infections (STIs) have been proposed as potential cofactors in anal carcinogenesis. The objectives of this study are to evaluate the relationship between asymptomatic bacterial anal STIs, the presence of HGAIN, and the diversity of oncogenic HPV genotypes in a cohort of MSM and TW living with HIV. A prospective study (June 2017–December 2023) was conducted at Son Llàtzer University Hospital (Palma de Mallorca, Spain), including 377 PLHIV (370 MSM, 7 TW). Anal cytology, detection of 14 oncogenic HPV genotypes, and screening for Chlamydia trachomatis , Neisseria gonorrhoeae , and Mycoplasma genitalium (from 2020 onward) were performed. Participants with abnormal cytology and/or HPV-16/18 underwent high-resolution anoscopy and biopsy. A total of 715 screening procedures were performed. Mean age was 44 years; 89% had an undetectable HIV viral load. The prevalence of bacterial STIs was 5.9% ( N = 42/715) for Chlamydia trachomatis , 2.8% ( N = 20/715) for Neisseria gonorrhoeae , and 10.3% ( N = 45/438) for Mycoplasma genitalium . Oncogenic HPV was detected in 62.6% of samples, with HPV-16 being the most frequent genotype. Participants with bacterial STIs showed greater diversity of oncogenic HPV genotypes, particularly the association of C. trachomatis with HPV-16 and HPV-59, and N. gonorrhoeae with HPV-18, HPV-33 and HPV-68. Although no statistically significant differences in HGAIN rates were observed, individuals with bacterial STIs and high-risk HPV showed a numerically higher proportion of abnormal cytology. Asymptomatic bacterial anal STIs were common among MSM and TW living with HIV and were associated with greater oncogenic HPV diversity. Although no statistically significant association with HGAIN was demonstrated, the observed pattern may indicate that bacterial STIs influence HPV genotype distribution. Given the established role of specific high-risk genotypes, particularly HPV-16, in anal carcinogenesis, alterations in genotype distribution could theoretically contribute to carcinogenic pathways; however, no causal inference can be made, and longitudinal studies are needed to clarify their potential clinical implications. In this context, integrating bacterial STI screening into anal dysplasia surveillance programs may contribute to a more comprehensive approach to sexual health care in PLHIV.
- 9 April 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessImpact of bacterial sexually transmitted infections on human papillomavirus and anal dysplasia in people living with HIV
Anal carcinoma is a relevant malignancy with increased incidence among people living with HIV (PLHIV), particularly in men who have sex with men (MSM) and transgender women (TW). Its main precursor lesion, high-grade anal intraepithelial neoplasia (HGAIN), is primarily associated with persistent infection with human papillomavirus (HPV). However, bacterial sexually transmitted infections (STIs) have been proposed as potential cofactors in anal carcinogenesis. The objectives of this study are to evaluate the relationship between asymptomatic bacterial anal STIs, the presence of HGAIN, and the diversity of oncogenic HPV genotypes in a cohort of MSM and TW living with HIV. A prospective study (June 2017–December 2023) was conducted at Son Llàtzer University Hospital (Palma de Mallorca, Spain), including 377 PLHIV (370 MSM, 7 TW). Anal cytology, detection of 14 oncogenic HPV genotypes, and screening for Chlamydia trachomatis , Neisseria gonorrhoeae , and Mycoplasma genitalium (from 2020 onward) were performed. Participants with abnormal cytology and/or HPV-16/18 underwent high-resolution anoscopy and biopsy. A total of 715 screening procedures were performed. Mean age was 44 years; 89% had an undetectable HIV viral load. The prevalence of bacterial STIs was 5.9% ( N = 42/715) for Chlamydia trachomatis , 2.8% ( N = 20/715) for Neisseria gonorrhoeae , and 10.3% ( N = 45/438) for Mycoplasma genitalium . Oncogenic HPV was detected in 62.6% of samples, with HPV-16 being the most frequent genotype. Participants with bacterial STIs showed greater diversity of oncogenic HPV genotypes, particularly the association of C. trachomatis with HPV-16 and HPV-59, and N. gonorrhoeae with HPV-18, HPV-33 and HPV-68. Although no statistically significant differences in HGAIN rates were observed, individuals with bacterial STIs and high-risk HPV showed a numerically higher proportion of abnormal cytology. Asymptomatic bacterial anal STIs were common among MSM and TW living with HIV and were associated with greater oncogenic HPV diversity. Although no statistically significant association with HGAIN was demonstrated, the observed pattern may indicate that bacterial STIs influence HPV genotype distribution. Given the established role of specific high-risk genotypes, particularly HPV-16, in anal carcinogenesis, alterations in genotype distribution could theoretically contribute to carcinogenic pathways; however, no causal inference can be made, and longitudinal studies are needed to clarify their potential clinical implications. In this context, integrating bacterial STI screening into anal dysplasia surveillance programs may contribute to a more comprehensive approach to sexual health care in PLHIV.
- Open Access
- 2 June 2022
- Published by Ediciones Universidad de Salamanca in Revista de Medicina y Cine
- Vol. 18 (2) , 97-107
Literatura y cine como formación humanística entre estudiantes y médicos en Mallorca
Objetivos: conocer las preferencias de cine y literatura de estudiantes de medicina y médicos en ejercicio. Metodología: encuesta entre estudiantes, médicos internos residentes (MIR) y facultativos especialistas de área (FEA) de dos hospitales de Mallorca. Resultados: 217 estudiantes (73,3% mujeres), 70 MIR/FEA jóvenes (71,4% mujeres) y 40 FEA senior (47,6% mujeres). Más del 90% refirieron su afición al cine o lectura. Se observaron diferencias por tipo de películas o libros entre los grupos. Los formatos clásicos fueron seleccionados mayoritariamente: sala de cine 57,9% vs 70% vs 71,4%; libro de papel 93,9% vs 93,4% vs 85,7%. Se observó una asociación positiva entre edad e incremento de consumo de cine y literatura. Conclusiones: los resultados de esta encuesta ponen de manifiesto diferencias etarias en el consumo de cine y literatura aunque este consumo parece más enfocado a la evasión y al entretenimiento.
- 2 June 2022
- Published by Ediciones Universidad de Salamanca in Revista de Medicina y Cine
- Vol. 18 (2) , 97-107
Open AccessLiteratura y cine como formación humanística entre estudiantes y médicos en Mallorca
Objetivos: conocer las preferencias de cine y literatura de estudiantes de medicina y médicos en ejercicio. Metodología: encuesta entre estudiantes, médicos internos residentes (MIR) y facultativos especialistas de área (FEA) de dos hospitales de Mallorca. Resultados: 217 estudiantes (73,3% mujeres), 70 MIR/FEA jóvenes (71,4% mujeres) y 40 FEA senior (47,6% mujeres). Más del 90% refirieron su afición al cine o lectura. Se observaron diferencias por tipo de películas o libros entre los grupos. Los formatos clásicos fueron seleccionados mayoritariamente: sala de cine 57,9% vs 70% vs 71,4%; libro de papel 93,9% vs 93,4% vs 85,7%. Se observó una asociación positiva entre edad e incremento de consumo de cine y literatura. Conclusiones: los resultados de esta encuesta ponen de manifiesto diferencias etarias en el consumo de cine y literatura aunque este consumo parece más enfocado a la evasión y al entretenimiento.
- Open Access
- 27 May 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (11) , 3039
Reinforcement of the Standard Therapy with Two Infusions of Convalescent Plasma for Patients with COVID-19: A Randomized Clinical Trial
Background: The aim was to evaluate the reinforcement of the standard therapy with hyperimmune plasma (HP) in Coronavirus-19 disease (COVID-19) patients. Methods: Open-label, multicenter, randomized clinical trial performed in three hospitals in the Balearic Islands. Non-severe COVID-19 hospitalized patients with clinical time evolution equal to/less than 7 days were included, and randomized in: plasma group (PG) (n = 37), receiving 600 mL divided into two doses from convalescent plasma donor, administered on days 1 and 2 after the enrollment; and control group (CG) (n = 17). Primary outcome was the time for clinical improvement within 21 days, defined as patient achievement of categories 8, 7, and 6 in the Adaptive COVID-19 Treatment Trial scale (ACTT). The trial was terminated early due to the impossibility of recruitment due to the pandemic. Results: PG presented better scores on the ACTT scale at 7 days after HP infusion, whereas CG was needed 14 days to achieve similar results. The plasma infusion was safe. Conclusions: Despite the tendency observed in the plasma group to achieve slightly earlier better physical condition compared with the standard treatment alone. The administration of HP has been shown to be a safe therapy. No robust evidence was found to affirm a therapeutic effect of the early administration of two infusions of HP for non-severe COVID-19 infected patients. The interpretation is limited by the early termination of the trial, which resulted in a small sample size.
- 27 May 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (11) , 3039
Open AccessReinforcement of the Standard Therapy with Two Infusions of Convalescent Plasma for Patients with COVID-19: A Randomized Clinical Trial
Background: The aim was to evaluate the reinforcement of the standard therapy with hyperimmune plasma (HP) in Coronavirus-19 disease (COVID-19) patients. Methods: Open-label, multicenter, randomized clinical trial performed in three hospitals in the Balearic Islands. Non-severe COVID-19 hospitalized patients with clinical time evolution equal to/less than 7 days were included, and randomized in: plasma group (PG) (n = 37), receiving 600 mL divided into two doses from convalescent plasma donor, administered on days 1 and 2 after the enrollment; and control group (CG) (n = 17). Primary outcome was the time for clinical improvement within 21 days, defined as patient achievement of categories 8, 7, and 6 in the Adaptive COVID-19 Treatment Trial scale (ACTT). The trial was terminated early due to the impossibility of recruitment due to the pandemic. Results: PG presented better scores on the ACTT scale at 7 days after HP infusion, whereas CG was needed 14 days to achieve similar results. The plasma infusion was safe. Conclusions: Despite the tendency observed in the plasma group to achieve slightly earlier better physical condition compared with the standard treatment alone. The administration of HP has been shown to be a safe therapy. No robust evidence was found to affirm a therapeutic effect of the early administration of two infusions of HP for non-severe COVID-19 infected patients. The interpretation is limited by the early termination of the trial, which resulted in a small sample size.
- Open Access
DOLAVI Real-Life Study of Dolutegravir Plus Lamivudine in Naive HIV-1 Patients (48 Weeks)
Brief: Real-world data in naïve HIV-1 patients demonstrate that dolutegravir plus lamivudine in a multiple tablet regimen is effective, safe, and satisfactory; it causes moderately increasing weight and abdominal circumference and is administrable on a test-and-treat strategy. Background: Our objectives were to determine the real-life effectiveness and safety of DT with dolutegravir (50 mg/QD) plus lamivudine (300 mg/QD) in a multiple-tablet regimen (MTR) in naïve PLHIV followed up for 48 weeks and to evaluate the compliance and satisfaction of patients. Material and methods: An open, single-arm, multicenter, non-randomized clinical trial from May 2019 through September 2020 with a 48-week follow-up. Results: The study included 88 PLHIV patients (87.5% male) with a mean age of 35.9 years; 76.1% were MSM patients. The mean baseline CD4 was 516.4 cells/uL, with a viral load (VL) of 4.49 log10, and 11.4% were in the AIDS stage. DT started within 7 days of first specialist consultation in all patients and the same day in 84.1%; 3.4% had baseline resistance mutations (K103N, V106I + E138A, and V108I); 12.5% were lost to follow-up. At week 48, 86.3% had VL < 50 cop/uL by intention-to-treat analysis and 98.7% by per-protocol (PP) analysis. Virological failure (VF) was recorded in 1.1%, with no resistance mutation. One blip was detected in 5.2% without VF. Three reported anxiety, dizziness, and cephalgia, respectively, at week 4 and one reported insomnia at week 24; none reported adverse events at week 48. The mean weight was 4 kg higher at 48 weeks (p = 0.0001) and abdominal circumference 3 cm larger at 24 weeks (p = 0.022). No forgetfulness occurred in 98.7% of patients. Patient satisfaction was 90/100 at 4, 24, and 48 weeks. Conclusion: Real-world data demonstrate that dolutegravir plus lamivudine in MTR is effective, safe, and satisfactory, moderately increasing weight and abdominal circumference and administrable on a test-and-treat strategy.
Open AccessDOLAVI Real-Life Study of Dolutegravir Plus Lamivudine in Naive HIV-1 Patients (48 Weeks)
Brief: Real-world data in naïve HIV-1 patients demonstrate that dolutegravir plus lamivudine in a multiple tablet regimen is effective, safe, and satisfactory; it causes moderately increasing weight and abdominal circumference and is administrable on a test-and-treat strategy. Background: Our objectives were to determine the real-life effectiveness and safety of DT with dolutegravir (50 mg/QD) plus lamivudine (300 mg/QD) in a multiple-tablet regimen (MTR) in naïve PLHIV followed up for 48 weeks and to evaluate the compliance and satisfaction of patients. Material and methods: An open, single-arm, multicenter, non-randomized clinical trial from May 2019 through September 2020 with a 48-week follow-up. Results: The study included 88 PLHIV patients (87.5% male) with a mean age of 35.9 years; 76.1% were MSM patients. The mean baseline CD4 was 516.4 cells/uL, with a viral load (VL) of 4.49 log10, and 11.4% were in the AIDS stage. DT started within 7 days of first specialist consultation in all patients and the same day in 84.1%; 3.4% had baseline resistance mutations (K103N, V106I + E138A, and V108I); 12.5% were lost to follow-up. At week 48, 86.3% had VL < 50 cop/uL by intention-to-treat analysis and 98.7% by per-protocol (PP) analysis. Virological failure (VF) was recorded in 1.1%, with no resistance mutation. One blip was detected in 5.2% without VF. Three reported anxiety, dizziness, and cephalgia, respectively, at week 4 and one reported insomnia at week 24; none reported adverse events at week 48. The mean weight was 4 kg higher at 48 weeks (p = 0.0001) and abdominal circumference 3 cm larger at 24 weeks (p = 0.022). No forgetfulness occurred in 98.7% of patients. Patient satisfaction was 90/100 at 4, 24, and 48 weeks. Conclusion: Real-world data demonstrate that dolutegravir plus lamivudine in MTR is effective, safe, and satisfactory, moderately increasing weight and abdominal circumference and administrable on a test-and-treat strategy.
- Open Access
Evolution, Clinical and Microbiological Characteristics of Invasive Pneumococcal Disease since the Introduction of the Pneumococcal Conjugate Vaccine 13-Valent in Adults over 18 Years Old
Invasive pneumococcal disease (IPD) presents high mortality in the population at risk. The aim of this work is to know the evolution, clinical and microbiological characteristics of IPD in the adult population of Majorca, since the introduction of a public funded program for pneumococcal conjugate vaccine (PCV-13) in the pediatric population in the Balearic Islands in 2016. For this purpose, a retrospective multicenter study was carried out in which all episodes of IPD in adult patients from the four hospitals of the public health system of Majorca were included, comparing the periods between 2012 and 2015 and between 2016 and 2019. Clinical variables, serotypes and antibiotic sensitivity were collected. There were 498 cases of IPD; 56.8% were male with a mean age of 67 (standard deviation: 16). Most infections were bacterial pneumonias (73.7%). Of the total cases, 264 (53%) presented complications. Of the 498 cases, 351 strains were obtained, of which 145 (41.3%) belong to vaccinal serotypes (included in the PCV-13 vaccine) and 206 (58.7%) to non-vaccinal serotypes (not included in the PCV-13 vaccine). The percentage of IPD caused by vaccinal serotypes was lower in the second period (47.8% vs. 34.5%; p = 0.012).
Open AccessEvolution, Clinical and Microbiological Characteristics of Invasive Pneumococcal Disease since the Introduction of the Pneumococcal Conjugate Vaccine 13-Valent in Adults over 18 Years Old
Invasive pneumococcal disease (IPD) presents high mortality in the population at risk. The aim of this work is to know the evolution, clinical and microbiological characteristics of IPD in the adult population of Majorca, since the introduction of a public funded program for pneumococcal conjugate vaccine (PCV-13) in the pediatric population in the Balearic Islands in 2016. For this purpose, a retrospective multicenter study was carried out in which all episodes of IPD in adult patients from the four hospitals of the public health system of Majorca were included, comparing the periods between 2012 and 2015 and between 2016 and 2019. Clinical variables, serotypes and antibiotic sensitivity were collected. There were 498 cases of IPD; 56.8% were male with a mean age of 67 (standard deviation: 16). Most infections were bacterial pneumonias (73.7%). Of the total cases, 264 (53%) presented complications. Of the 498 cases, 351 strains were obtained, of which 145 (41.3%) belong to vaccinal serotypes (included in the PCV-13 vaccine) and 206 (58.7%) to non-vaccinal serotypes (not included in the PCV-13 vaccine). The percentage of IPD caused by vaccinal serotypes was lower in the second period (47.8% vs. 34.5%; p = 0.012).
- 1 September 2020
- Published by Elsevier in Archivos de Bronconeumología
- Vol. 56 (9) , 551-558
Eventos cardiovasculares tempranos y tardíos en pacientes ingresados por neumonía adquirida en la comunidad
- 1 September 2020
- Published by Elsevier in Archivos de Bronconeumología
- Vol. 56 (9) , 551-558
Eventos cardiovasculares tempranos y tardíos en pacientes ingresados por neumonía adquirida en la comunidad
- Open Access
- 24 July 2020
- Published by MDPI AG in Microorganisms
- Vol. 8 (8) , 1106
Low Albumin Levels Are Associated with Poorer Outcomes in a Case Series of COVID-19 Patients in Spain: A Retrospective Cohort Study
There is limited information available describing the clinical and epidemiological features of Spanish patients requiring hospitalization for coronavirus disease 2019 (COVID-19). In this observational study, we aimed to describe the clinical characteristics and epidemiological features of severe (non-ICU) and critically patients (ICU) with COVID-19 at triage, prior to hospitalization. Forty-eight patients (27 non-ICU and 21 ICU) with positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection were analyzed (mean age, 66 years, [range, 33–88 years]; 67% males). There were no differences in age or sex among groups. Initial symptoms included fever (100%), coughing (85%), dyspnea (76%), diarrhea (42%) and asthenia (21%). ICU patients had a higher prevalence of dyspnea compared to non-ICU patients (95% vs. 61%, p = 0.022). ICU-patients had lymphopenia as well as hypoalbuminemia. Lactate dehydrogenase (LDH), C-reactive protein (CRP), and procalcitonin were significantly higher in ICU patients compared to non-ICU (p < 0.001). Lower albumin levels were associated with poor prognosis measured as longer hospital length (r = −0.472, p < 0.001) and mortality (r = −0.424, p = 0.003). As of 28 April 2020, 10 patients (8 ICU and 2 non-ICU) have died (21% mortality), and while 100% of the non-ICU patients have been discharged, 33% of the ICU patients still remained hospitalized (5 in ICU and 2 had been transferred to ward). Critically ill patients with COVID-19 present lymphopenia, hypoalbuminemia and high levels of inflammation.
- 24 July 2020
- Published by MDPI AG in Microorganisms
- Vol. 8 (8) , 1106
Open AccessLow Albumin Levels Are Associated with Poorer Outcomes in a Case Series of COVID-19 Patients in Spain: A Retrospective Cohort Study
There is limited information available describing the clinical and epidemiological features of Spanish patients requiring hospitalization for coronavirus disease 2019 (COVID-19). In this observational study, we aimed to describe the clinical characteristics and epidemiological features of severe (non-ICU) and critically patients (ICU) with COVID-19 at triage, prior to hospitalization. Forty-eight patients (27 non-ICU and 21 ICU) with positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection were analyzed (mean age, 66 years, [range, 33–88 years]; 67% males). There were no differences in age or sex among groups. Initial symptoms included fever (100%), coughing (85%), dyspnea (76%), diarrhea (42%) and asthenia (21%). ICU patients had a higher prevalence of dyspnea compared to non-ICU patients (95% vs. 61%, p = 0.022). ICU-patients had lymphopenia as well as hypoalbuminemia. Lactate dehydrogenase (LDH), C-reactive protein (CRP), and procalcitonin were significantly higher in ICU patients compared to non-ICU (p < 0.001). Lower albumin levels were associated with poor prognosis measured as longer hospital length (r = −0.472, p < 0.001) and mortality (r = −0.424, p = 0.003). As of 28 April 2020, 10 patients (8 ICU and 2 non-ICU) have died (21% mortality), and while 100% of the non-ICU patients have been discharged, 33% of the ICU patients still remained hospitalized (5 in ICU and 2 had been transferred to ward). Critically ill patients with COVID-19 present lymphopenia, hypoalbuminemia and high levels of inflammation.
- 11 December 2019
- Published by Springer Nature in Journal of Clinical Immunology
- Vol. 40 (1) , 203-210
Should MASP-2 Deficiency Be Considered a Primary Immunodeficiency? Relevance of the Lectin Pathway
Mannose-binding lectin (MBL)-associated serine protease-2 (MASP-2) is an indispensable enzyme for the activation of the lectin pathway of complement. Its deficiency is classified as a primary immunodeficiency associated to pyogenic bacterial infections, inflammatory lung disease, and autoimmunity. In Europeans, MASP-2 deficiency, due to homozygosity for c.359A > G (p.D120G), occurs in 7 to 14/10,000 individuals. We analyzed the presence of the p.D120G mutation in adults (increasing the sample size of our previous studies) and children. Different groups of patients (1495 adults hospitalized with community-acquired pneumonia, 186 adults with systemic lupus erythematosus, 103 pediatric patients with invasive pneumococcal disease) and control individuals (1119 healthy adult volunteers, 520 adult patients without history of relevant infectious diseases, and a pediatric control group of 311 individuals) were studied. Besides our previously reported MASP-2-deficient healthy adults, we found a new p.D120G homozygous individual from the pediatric control group. We also reviewed p.D120G homozygous individuals reported so far: a total of eleven patients with a highly heterogeneous range of disorders and nine healthy controls (including our four MASP-2-deficient individuals) have been identified by chance in association studies. Individuals with complete deficiencies of several pattern recognition molecules of the lectin pathway (MBL, collectin-10 and collectin-11, and ficolin-3) as well as of MASP-1 and MASP-3 have also been reviewed. Cumulative evidence suggests that MASP-2, and even other components of the LP, are largely redundant in human defenses and that individuals with MASP-2 deficiency do not seem to be particularly prone to infectious or autoimmune diseases.
- 11 December 2019
- Published by Springer Nature in Journal of Clinical Immunology
- Vol. 40 (1) , 203-210
Should MASP-2 Deficiency Be Considered a Primary Immunodeficiency? Relevance of the Lectin Pathway
Mannose-binding lectin (MBL)-associated serine protease-2 (MASP-2) is an indispensable enzyme for the activation of the lectin pathway of complement. Its deficiency is classified as a primary immunodeficiency associated to pyogenic bacterial infections, inflammatory lung disease, and autoimmunity. In Europeans, MASP-2 deficiency, due to homozygosity for c.359A > G (p.D120G), occurs in 7 to 14/10,000 individuals. We analyzed the presence of the p.D120G mutation in adults (increasing the sample size of our previous studies) and children. Different groups of patients (1495 adults hospitalized with community-acquired pneumonia, 186 adults with systemic lupus erythematosus, 103 pediatric patients with invasive pneumococcal disease) and control individuals (1119 healthy adult volunteers, 520 adult patients without history of relevant infectious diseases, and a pediatric control group of 311 individuals) were studied. Besides our previously reported MASP-2-deficient healthy adults, we found a new p.D120G homozygous individual from the pediatric control group. We also reviewed p.D120G homozygous individuals reported so far: a total of eleven patients with a highly heterogeneous range of disorders and nine healthy controls (including our four MASP-2-deficient individuals) have been identified by chance in association studies. Individuals with complete deficiencies of several pattern recognition molecules of the lectin pathway (MBL, collectin-10 and collectin-11, and ficolin-3) as well as of MASP-1 and MASP-3 have also been reviewed. Cumulative evidence suggests that MASP-2, and even other components of the LP, are largely redundant in human defenses and that individuals with MASP-2 deficiency do not seem to be particularly prone to infectious or autoimmune diseases.
- Open Access
- 5 October 2019
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 75 (1) , 208-214
Factors associated with the number of drugs in darunavir/cobicistat regimens
Darunavir/cobicistat can be used as mono, dual, triple or more than triple therapy. To assess factors associated with the number of drugs in darunavir/cobicistat regimens. A nationwide retrospective cohort study of consecutive HIV-infected patients initiating darunavir/cobicistat in Spain from July 2015 to May 2017. Baseline characteristics, efficacy and safety at 48 weeks were compared according to the number of drugs used. There were 761 patients (75% men, 98% were antiretroviral-experienced, 32% had prior AIDS, 84% had HIV RNA 3) who initiated darunavir/cobicistat as mono (n=308, 40%), dual (n=173, 23%), triple (n=253, 33%) or four-drug (n=27, 4%) therapy. Relative to monotherapy, triple therapy was more common in men aged 3 and with detectable viral load at initiation of darunavir/cobicistat; dual therapy was more common with previous intravenous drug use, detectable viral load at initiation of darunavir/cobicistat and no prior darunavir plus ritonavir; and four-drug therapy was more common with prior AIDS and detectable viral load at initiation of darunavir/cobicistat. Monotherapy and dual therapy showed a trend to better virological responses than triple therapy. CD4 responses and adverse effects did not differ among regimens. Darunavir/cobicistat use in Spain has been tailored according to clinical characteristics of HIV-infected patients. Monotherapy and dual therapy have been common and preferentially addressed to older patients with a better HIV status, suggesting that health issues other than HIV infection may have been strong determinants of its prescription.
- 5 October 2019
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 75 (1) , 208-214
Open AccessFactors associated with the number of drugs in darunavir/cobicistat regimens
Darunavir/cobicistat can be used as mono, dual, triple or more than triple therapy. To assess factors associated with the number of drugs in darunavir/cobicistat regimens. A nationwide retrospective cohort study of consecutive HIV-infected patients initiating darunavir/cobicistat in Spain from July 2015 to May 2017. Baseline characteristics, efficacy and safety at 48 weeks were compared according to the number of drugs used. There were 761 patients (75% men, 98% were antiretroviral-experienced, 32% had prior AIDS, 84% had HIV RNA 3) who initiated darunavir/cobicistat as mono (n=308, 40%), dual (n=173, 23%), triple (n=253, 33%) or four-drug (n=27, 4%) therapy. Relative to monotherapy, triple therapy was more common in men aged 3 and with detectable viral load at initiation of darunavir/cobicistat; dual therapy was more common with previous intravenous drug use, detectable viral load at initiation of darunavir/cobicistat and no prior darunavir plus ritonavir; and four-drug therapy was more common with prior AIDS and detectable viral load at initiation of darunavir/cobicistat. Monotherapy and dual therapy showed a trend to better virological responses than triple therapy. CD4 responses and adverse effects did not differ among regimens. Darunavir/cobicistat use in Spain has been tailored according to clinical characteristics of HIV-infected patients. Monotherapy and dual therapy have been common and preferentially addressed to older patients with a better HIV status, suggesting that health issues other than HIV infection may have been strong determinants of its prescription.
- 1 September 2019
- Published by Elsevier in Reumatología Clínica
- Vol. 15 (5) , e62-e65
Afectación osteoarticular por Streptococcus pneumoniae tras la autorización de las vacunas conjugadas
- 1 September 2019
- Published by Elsevier in Reumatología Clínica
- Vol. 15 (5) , e62-e65
Afectación osteoarticular por Streptococcus pneumoniae tras la autorización de las vacunas conjugadas